Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to…”In the company’s words, NCT02525263 on ClinicalTrials.gov
- Tested for
- Chronic Kidney Disease, Type 2 Diabetes
- Main trialPhase 2
- “A Phase II, Open-Label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (RMTX-CL001). NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. All enrolled subjects will be treated with up to two injections of NKA at least 6 months apart.”In the company’s words, NCT02525263 on ClinicalTrials.gov
Other drugs for Chronic Kidney Disease
- MT1013Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Phase 3
- BaxdrostatAstraZeneca · Phase 3
- EmpagliflozinBoehringer Ingelheim · Phase 3
- Migalastat HClAmicus Therapeutics · Phase 3
- VicadrostatBoehringer Ingelheim · Phase 3
- XyloCore StrenghtIperboreal Pharma Srl · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Terminated | May 2017 | Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026